NCT03933488 is a Phase 1 clinical trial of TAK-994 in Healthy Participants, sponsored by Takeda.

Who is sponsoring NCT03933488?

NCT03933488 is sponsored by Takeda.

What drugs are being tested in NCT03933488?

Interventions in NCT03933488: TAK-994, TAK-994 Placebo.

What condition does NCT03933488 study?

NCT03933488 studies Healthy Participants.

Is NCT03933488 still recruiting?

NCT03933488 is currently completed. Last updated 24 June 2020.

Last reviewed 2020-06-24 · How we verify

NCT03933488

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Completed Phase 1 Last updated 24 June 2020

What this trial tests

Phase 1 trial testing TAK-994 in Healthy Participants in 121 participants. Completed in 29 March 2020.

Timeline

1 May 2019

Primary endpoint
29 March 2020

29 March 2020

Quick facts

Lead sponsor	Takeda
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	other
Enrollment	121
Start date	1 May 2019
Primary completion	29 March 2020
Estimated completion	29 March 2020
Sites	2 locations across United States

Drugs / interventions tested

TAK-994 — full drug profile →
TAK-994 Placebo

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and tolerability of TAK-994 following single and multiple oral doses in healthy non-Japanese and Japanese adult participants and healthy elderly participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hypocretin (Orexin) Replacement Therapies.
Seigneur E, de Lecea L. · · 2020 · cited 8× · PMID 38738170 · DOI 10.1016/j.medidd.2020.100070

Verify or expand the search:

Other trials of TAK-994

Trials testing the same drug.

NCT04820842 — A Study of TAK-994 in Adults With Narcolepsy · Phase 2 · terminated
NCT04745767 — A Study of Different Forms of TAK-994 in Healthy Adults · Phase 1 · completed
NCT04551079 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sl · Phase 1 · completed
NCT04096560 — A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy · Phase 2 · terminated

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03933488 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 24 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03933488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing